🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07639619
Starting soon Not applicable

Robot Assisted Minimally Invasive Treatment Versus Conventional Surgery for FFP3-4 Fragility Fractures of the Pelvis in Elderly Patients

NCT07639619 · tracked via the Priya Life Science China tracker
Sponsor
Junbo Liang
Phase
Not applicable
Started
2026-06-01
Last updated
2026-06-10

Condition(s) studied

Fragility Fractures of the Pelvis (FFP)Osteoporosis

Investigational drug(s) / intervention(s)

Robot Assisted Minimally Invasive FixationConventional Open Fixation

Robot Assisted Minimally Invasive Fixation: Robot assisted minimally invasive fixation is performed using robotic navigation assisted percutaneous screw placement for stabilization of unstable pelvic fragility fractures.

Conventional Open Fixation: Conventional open reduction and internal fixation for FFP3-4 pelvic fragility fractures performed without robotic assistance.

Study summary

This prospective randomized controlled trial aims to compare the efficacy and safety of robot assisted minimally invasive treatment versus conventional surgery in elderly patients with FFP3-4 fragility fractures of the pelvis. Eligible patients will be stratified according to FFP classification and randomly assigned in a 1:1 ratio to receive either robot assisted minimally invasive fixation or conventional surgical treatment. Primary and secondary outcomes include pain relief, early mobilization, functional recovery, perioperative complications, venous thromboembolism events, laboratory parameters, imaging outcomes, and healthcare resource utilization. The study aims to provide evidence for optimizing surgical treatment strategies in elderly patients with unstable pelvic fragility fractures.

Eligibility

Sex
ALL
Min age
60 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 60 years * Low energy trauma * Diagnosis of osteoporosis * Diagnosis of FFP3 or FFP4 fragility fractures of the pelvis * Injury duration less than 3 weeks * Ability to provide written informed consent Exclusion Criteria: * Severe open injury or skin infection at the surgical site * Hemodynamic instability preventing anesthesia or surgery * Severe psychiatric disorders or dementia * Severe obesity affecting imaging quality * Severe systemic diseases preventing surgery * Pathological fracture * Current chemotherapy, radiotherapy, systemic corticosteroid therapy, or growth factor therapy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
No. 150 Ximen Road Linhai Zhejiang

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07639619 on ClinicalTrials.gov ↗ ← All trials in China